DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

All news

Neutral impactEarnings

63 moons technologies limited — Outcome of Board Meeting

NSE 4 hrs ago·21 Jul 2026, 11:51 am

63 Moons Technologies

63 Moons Technologies Limited has informed shareholders that its board has approved a strategic move to acquire equity shares in its subsidiary, Ticker Ltd. This transaction involves the subscription of newly issued shares by Financial Technologies Singapore, the wholly-owned overseas subsidiary of 63 Moons. Essentially, the group is consolidating ownership of Ticker Ltd. through this preferential allotment.

This development is significant for investors as it strengthens the group's control over its key subsidiary. By increasing the stake, 63 Moons aims to align the subsidiary's strategic goals more closely with the parent company. This consolidation is often viewed positively by the market as it can streamline operations and enhance the overall value of the group.

Investors should monitor the completion of this preferential allotment and any subsequent regulatory filings. The successful execution of this deal is expected to be a neutral to positive event for the stock, reflecting the company's focus on strengthening its core business structure and subsidiary management.